Gabelli Funds’s Nektar Therapeutics NKTR Stock Holding History

Gabelli Funds’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-233	Closed	-$213K	–	1153
2018 Q3	$213K	Buy	+233	New	+$199K	﹤0.01%	1101

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gabelli Funds's NKTR Position: Q4 2018 in Review

Gabelli Funds sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 233 shares — an estimated $213K sold.

Gabelli Funds first reported a position in NKTR in Q3 2018 and held it in 1 quarter. The position peaked at $213K in Q3 2018. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

Gabelli Funds reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
Gabelli Funds sold 233 Nektar Therapeutics shares in Q4 2018, an estimated $213K.
Gabelli Funds first reported a position in Nektar Therapeutics in Q3 2018 and held it in 1 quarter.
Gabelli Funds's Nektar Therapeutics position peaked at $213K in Q3 2018.
342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Gabelli Funds's 13F filing for Q4 2018, filed 30 Jan 2019.